{
  "docId": "019de071-dd7f-730a-8977-e46a36e30dcf",
  "docSlug": "abc22aebd2d55a5159142df321cabcee",
  "documentTitle": "Bionomics | IPO Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7391304,
  "pageNumber": 20,
  "pageCount": 38,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a process flow diagram to show the evolution of the drug program from initial trial results to the ongoing ATTUNE study.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-dd7f-730a-8977-e46a36e30dcf/20",
  "deckHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf",
  "deckJsonHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf.json",
  "deckAnchorHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Five-stage process flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72740532-d412-4fcf-b3a2-6903d284fa8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.12,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "*Primary endpoint of CAPS-5 total symptom severity score at 12 weeks",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4eaa8240-9ff2-4d03-9112-a7a89cc651c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.16,
        "x": 0.6,
        "y": 0.45
      },
      "kind": "list",
      "text": "Type C meeting with FDA; FDA granted Fast Track designation in PTSD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1eb0af27-8ff3-4800-9474-d32806dcbe6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.16,
        "x": 0.06,
        "y": 0.45
      },
      "kind": "list",
      "text": "Anti-depressant and anti-anxiety trends seen at earlier time points; Safety profile generally well tolerated; Did not meet primary endpoint; lower than expected exposure of liquid suspension formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45072fe8-7634-4c9e-a574-669b08830323",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.16,
        "x": 0.78,
        "y": 0.45
      },
      "kind": "list",
      "text": "Phase 2b ATTUNE trial started in July 2021; Topline data expected 1H 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "670a1f50-3983-49bc-9930-6c533f471ad0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.16,
        "x": 0.24,
        "y": 0.45
      },
      "kind": "list",
      "text": "Pharmacometric analysis of Phase 2 PTSD data; Predicted significant efficacy potential with adequate drug exposure achieved",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8421f26-b42c-4b05-9ae5-3adc814712db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.16,
        "x": 0.42,
        "y": 0.45
      },
      "kind": "list",
      "text": "New tablet formulation overcomes food effect of suspension formulation; Achieved exposure target predicted from pharmacometric analysis; Extended IP coverage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe2939af-7e56-435d-95d9-f0d589743d5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "BNC210 is Potentially Well-Positioned in Post-Traumatic Stress Disorder",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5daf55cf-f192-42d6-ab0d-c48b7472667c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "05383ff0-3fe8-4d53-ae0e-ef40f247fe18",
      "evidence": "The slide uses a diagram/process to illustrate the development process.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "88bc9154-0a47-4df8-9b5e-9c759944b494",
      "evidence": "Sequential flow of development stages",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fc1436cb-ff7e-477f-bab1-9f8cefcb616e",
      "evidence": "Slides 17-20 present the problem and potential solution for PTSD",
      "position": 0,
      "objective": "What is the cost of inaction for PTSD patients?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}